Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company pioneering novel therapies for fibrotic diseases through integrin biology and TGF-β pathway modulation. This page serves as the definitive source for official updates on their research pipeline, clinical trial progress, and regulatory developments.
Investors and researchers will find timely announcements about bexotegrast (PLN-74809), the company’s dual αvβ6/αvβ1 integrin inhibitor currently in Phase 2b trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The resource also covers updates across PLRX’s broader pipeline targeting liver fibrosis, oncology, and neuromuscular conditions.
Key content includes press releases on clinical milestones, peer-reviewed publication highlights, and strategic collaborations. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to PLRX’s latest advancements in small molecule therapeutics. Check regularly for updates on trial enrollment completions, data readouts, and FDA communications related to their antifibrotic programs.
Pliant Therapeutics, a clinical stage biotechnology company focused on fibrosis treatment, has announced participation in key virtual investor events. Management will take part in the Cowen 41st Annual Health Care Conference from March 1-4, 2021, with a panel discussion led by President and CEO Bernard Coulie on March 1 at 10:30 a.m. ET. Additionally, they will engage with investors on March 17 during Citi's 2021 Winter West Coast Biotech Virtual Bus Tour. Pliant's lead drug candidate is PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced the appointment of Dr. David Pyott to its Board of Directors, strengthening its leadership as the company advances its clinical stage portfolio. Dr. Pyott, former Chairman and CEO of Allergan, brings over 30 years of pharmaceutical experience, transforming Allergan into a global leader. He aims to support Pliant in developing innovative treatments for fibrosis. Pliant's lead candidate, PLN-74809, targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis, with ongoing Phase 2a trials.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Gregory P. Cosgrove, M.D., as Vice President of Clinical Development. Dr. Cosgrove will spearhead the strategic execution of the Idiopathic Pulmonary Fibrosis (IPF) clinical development program for PLN-74809, a dual selective inhibitor currently in Phase 2a trials. His extensive experience in pulmonary fibrosis research is expected to enhance Pliant's clinical efforts. PLN-74809 has received Orphan Drug Designation from the FDA for both IPF and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced its participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company will feature a fireside chat with CEO Bernard Coulie on November 23, 2020, at 10:00 AM ET, available on their website. Pliant focuses on developing therapies for fibrosis, with lead candidate PLN-74809 in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The session will be archived for 90 days post-event.
Pliant Therapeutics (Nasdaq: PLRX) reported its Q3 2020 results, highlighting significant progress in clinical programs despite COVID-19 challenges. The company successfully executed its IPO and advanced multiple indications in its pipeline, notably PLN-74809 for idiopathic pulmonary fibrosis and COVID-19 related ARDS. Financially, the company experienced related party revenue of $4.8 million, with R&D expenses rising to $16.9 million, leading to a net loss of $16.5 million. Pliant maintains a strong cash position of $294 million, sufficient to fund operations into 2023.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) will present a poster at The Liver Meeting® 2020, hosted by AASLD, from November 13-16, 2020. The poster, titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis" (Abstract #0321), will be available online for registered participants. Pliant, focused on fibrosis treatment, has two main candidates: PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474, in Phase 1 trials for liver fibrosis associated with NASH.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Mike Ouimette as the new general counsel and corporate secretary. Bringing over 20 years of legal expertise, Ouimette previously held executive positions at Portola Pharmaceuticals and Onyx Pharmaceuticals. His appointment aims to enhance Pliant's legal and regulatory strategies as the company progresses its lead drug candidate, PLN-74809, through Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Pliant focuses on developing innovative therapies for treating fibrosis.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its data presentation on PLN-74809 during the ATS 2020 Virtual Sessions on Sept. 24, 2020. PLN-74809 is an oral dual selective integrin inhibitor being evaluated for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The treatment has received Orphan Drug Designation by the FDA for both indications and is currently in Phase 2a trials for IPF and PSC. The presentation will be accessible to registered attendees until Nov. 10, 2020.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm specializing in fibrosis treatments, will participate in investor conferences during September 2020. Key events include Citi's 15th Annual BioPharma Conference from September 8-11, where Scott Turner, Ph.D., will discuss COVID-19 therapeutics on September 9 at 9:50 a.m. EDT. Additionally, the company will attend Cantor Fitzgerald's Virtual Global Healthcare Conference from September 15-17. More details and access to presentations can be found on the Pliant Therapeutics Investors page.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in The Digital International Liver Congress 2020, showcasing data on PLN-74809 for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The oral presentation highlights PLN-74809 as a dual integrin inhibitor that reduces fibrosis in preclinical models. Additionally, a poster presentation will discuss collagen gene expression reduction in liver tissue from cirrhotic patients. Pliant is in Phase 2a trials for PLN-74809 and is also developing PLN-1474 for liver fibrosis related to nonalcoholic steatohepatitis (NASH).
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
